Trial Profile
A Multicenter, Double-blind, Randomized Safety and Efficacy Study of Two Dose Levels of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Taliglucerase alfa (Primary)
- Indications Gaucher's disease
- Focus Registrational; Therapeutic Use
- Sponsors Protalix Biotherapeutics
- 28 Aug 2014 Data from this trial were used to support the FDA approval of taliglucerase alpha in paediatric patients with type 1 Gaucher's disease, according to a media release from Pfizer and Protalix BioTherapeutics.
- 20 Jun 2014 New trial record